Senior insider sale
CHIEF MEDICAL OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$3.92M
135K shares
What this filing means
COLLINS HELEN LOUISE plans to sell 135K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $3.92M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 3/25/2026ACC: 0001974158-26-000026
Officer· CHIEF MEDICAL OFFICER
Since Feb 2026
135K
Shares to sell
$3.92M
Approx. market value
45K
Acquired (3 months)
1
Planned
4 completed
Securities Acquired — Last 3 Months1
Stock Options
N/A
8/9/2022
45KTotal acquired45K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/9/2022 | Stock Options N/A | 45K | — |
| Total | 45K | ||
Planned & Completed Dispositions5
Completed
—Completed
Units to sell
5K
Market value
$138.8K
3/17/2026
—Completed
Units to sell
10.13K
Market value
$305.8K
3/10/2026
—Completed
Units to sell
29.87K
Market value
$896.8K
3/9/2026
—Completed
Units to sell
45K
Market value
$1.18M
2/17/2026
Planned — Approximate Date
NasdaqPlanned
Units to sell
45K
Market value
$1.40M
3/25/2026
Total
Units
135K
Value
$3.92M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
3/17/2026 | 5K | $138.8K | — | Completed |
3/10/2026 | 10.13K | $305.8K | — | Completed |
3/9/2026 | 29.87K | $896.8K | — | Completed |
2/17/2026 | 45K | $1.18M | — | Completed |
| Planned — Approximate Date | ||||
3/25/2026 | 45K | $1.40M | Nasdaq | Planned |
| Total | 135K | $3.92M | ||